» Articles » PMID: 26630001

Silica Vesicle Nanovaccine Formulations Stimulate Long-Term Immune Responses to the Bovine Viral Diarrhoea Virus E2 Protein

Overview
Journal PLoS One
Date 2015 Dec 3
PMID 26630001
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Bovine Viral Diarrhoea Virus (BVDV) is one of the most serious pathogen, which causes tremendous economic loss to the cattle industry worldwide, meriting the development of improved subunit vaccines. Structural glycoprotein E2 is reported to be a major immunogenic determinant of BVDV virion. We have developed a novel hollow silica vesicles (SV) based platform to administer BVDV-1 Escherichia coli-expressed optimised E2 (oE2) antigen as a nanovaccine formulation. The SV-140 vesicles (diameter 50 nm, wall thickness 6 nm, perforated by pores of entrance size 16 nm and total pore volume of 0.934 cm3 g(-1)) have proven to be ideal candidates to load oE2 antigen and generate immune response. The current study for the first time demonstrates the ability of freeze-dried (FD) as well as non-FD oE2/SV140 nanovaccine formulation to induce long-term balanced antibody and cell mediated memory responses for at least 6 months with a shortened dosing regimen of two doses in small animal model. The in vivo ability of oE2 (100 μg)/SV-140 (500 μg) and FD oE2 (100 μg)/SV-140 (500 μg) to induce long-term immunity was compared to immunisation with oE2 (100 μg) together with the conventional adjuvant Quil-A from the Quillaja saponira (10 μg) in mice. The oE2/SV-140 as well as the FD oE2/SV-140 nanovaccine generated oE2-specific antibody and cell mediated responses for up to six months post the final second immunisation. Significantly, the cell-mediated responses were consistently high in mice immunised with oE2/SV-140 (1,500 SFU/million cells) at the six-month time point. Histopathology studies showed no morphological changes at the site of injection or in the different organs harvested from the mice immunised with 500 μg SV-140 nanovaccine compared to the unimmunised control. The platform has the potential for developing single dose vaccines without the requirement of cold chain storage for veterinary and human applications.

Citing Articles

The combination of vaccines and adjuvants to prevent the occurrence of high incidence of infectious diseases in bovine.

Yao Y, Zhang Z, Yang Z Front Vet Sci. 2023; 10:1243835.

PMID: 37885619 PMC: 10598632. DOI: 10.3389/fvets.2023.1243835.


A Glance on Nanovaccine: A Potential Approach for Disease Prevention.

Garg A, Agrawal R, Chopra H, Singh T, Chaudhary R, Tankara A Curr Pharm Biotechnol. 2023; 25(11):1406-1418.

PMID: 37861010 DOI: 10.2174/0113892010254221231006100659.


Enteritidis Bacteriophages Isolated from Kenyan Poultry Farms Demonstrate Time-Dependent Stability in Environments Mimicking the Chicken Gastrointestinal Tract.

Mhone A, Makumi A, Odaba J, Guantai L, Gunathilake K, Loignon S Viruses. 2022; 14(8).

PMID: 36016410 PMC: 9416366. DOI: 10.3390/v14081788.


Development of thermostable vaccine adjuvants.

Qi Y, Fox C Expert Rev Vaccines. 2021; 20(5):497-517.

PMID: 33724133 PMC: 8292183. DOI: 10.1080/14760584.2021.1902314.


Characterization of the Biodistribution of a Silica Vesicle Nanovaccine Carrying a Protective Antigen With Live Animal Imaging.

Mody K, Zhang B, Li X, Fletcher N, Akhter D, Jarrett S Front Bioeng Biotechnol. 2021; 8:606652.

PMID: 33537291 PMC: 7848120. DOI: 10.3389/fbioe.2020.606652.


References
1.
Perez Aguirreburualde M, Gomez M, Ostachuk A, Wolman F, Albanesi G, Pecora A . Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants. Vet Immunol Immunopathol. 2013; 151(3-4):315-24. DOI: 10.1016/j.vetimm.2012.12.004. View

2.
Mahony D, Cavallaro A, Stahr F, Mahony T, Qiao S, Mitter N . Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. Small. 2013; 9(18):3138-46. DOI: 10.1002/smll.201300012. View

3.
Mody K, Mahony D, Cavallaro A, Stahr F, Qiao S, Mahony T . Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditions. Int J Pharm. 2014; 465(1-2):325-32. DOI: 10.1016/j.ijpharm.2014.01.037. View

4.
Mahony D, Cavallaro A, Mody K, Xiong L, Mahony T, Qiao S . In vivo delivery of bovine viral diahorrea virus, E2 protein using hollow mesoporous silica nanoparticles. Nanoscale. 2014; 6(12):6617-26. DOI: 10.1039/c4nr01202j. View

5.
Mody K, Mahony D, Zhang J, Cavallaro A, Zhang B, Popat A . Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to Bovine Viral Diarrhoea Virus E2 protein. Biomaterials. 2014; 35(37):9972-9983. DOI: 10.1016/j.biomaterials.2014.08.044. View